Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

BMI1 inhibitor

DRUG CLASS:

BMI1 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	BMIi-1 Sensitive: B - Late Trials BMIi-1 Sensitive : B	BMIi-1 Sensitive: B - Late Trials BMIi-1 Sensitive : B
BMI1 overexpression	Glioblastoma	BMI1 overexpression	Glioblastoma	PTC-209 Sensitive: D – Preclinical PTC-209 Sensitive : D	PTC-209 Sensitive: D – Preclinical PTC-209 Sensitive : D
CD34 positive	Acute Myelogenous Leukemia	CD34 positive	Acute Myelogenous Leukemia	trametinib + BMIi-1 Sensitive: D – Preclinical trametinib + BMIi-1 Sensitive : D	trametinib + BMIi-1 Sensitive: D – Preclinical trametinib + BMIi-1 Sensitive : D
CD34 positive	Acute Myelogenous Leukemia	CD34 positive	Acute Myelogenous Leukemia	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D
CD34 positive + MN1 overexpression + MCL1 elevation	Acute Myelogenous Leukemia	CD34 positive + MN1 overexpression + MCL1 elevation	Acute Myelogenous Leukemia	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D
CD34 positive + BMI1 overexpression + MAP2K1 elevation	Acute Myelogenous Leukemia	CD34 positive + BMI1 overexpression + MAP2K1 elevation	Acute Myelogenous Leukemia	trametinib + BMIi-1 Sensitive: D – Preclinical trametinib + BMIi-1 Sensitive : D	trametinib + BMIi-1 Sensitive: D – Preclinical trametinib + BMIi-1 Sensitive : D